In a pancreatic cancer organoid drug screening study, researchers screened 76 non-clinical compounds and found that PRMT5 inhibitor EZP015556 could be a potential candidate for MTAP-negative pancreatic cancer (Driehuis et al., 2019). Here, PRMT5 is linked to familial pancreatic carcinoma.